Natalizumab discontinuation in a Dutch real-world cohort

被引：3

作者：

Coerver, E. M. E. ^{[1
]}

Wessels, M. H. J. ^{[1
]}

van Lierop, Z. Y. G. ^{[1
]}

van Kempen, Z. L. E. ^{[1
]}

Killestein, J. ^{[1
]}

Strijbis, E. M. M. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, MS Ctr Amsterdam, Amsterdam Neurosci, Dept Neurol,Amsterdam Univ Med Ctr, Amsterdam, Netherlands

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2021年 / 52卷

关键词：

Multiple sclerosis; Natalizumab; Treatment discontinuation; MS;

D O I：

10.1016/j.msard.2021.102974

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.

引用

页数：3

共 50 条

[31] Impact of Natalizumab on Economic and Clinical Outcomes in MS Patients in the Real-World Setting
Cai, Qian
Tan, Hiangkiat
Agarwal, Sonalee
Kamat, Siddhesh
NEUROLOGY, 2010, 74 (09) : A65 - A65
[32] A Machine Learning Approach to Real-World Time to Treatment Discontinuation Prediction
Meng, Weilin
Zhang, Xinyuan
Ru, Boshu
Guan, Yuanfang
ADVANCED INTELLIGENT SYSTEMS, 2023, 5 (04)
[33] Motives for quetiapine discontinuation in real-world clinical setting: a retrospective review
Parise, V. Fricchione
Addeo, L.
Laezza, R.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S528 - S529
[34] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
Norborg, Hilde
Riise, Trond
Myhr, Kjell-Morten
Grytten, Nina
Wergeland, Stig
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (02)
[35] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
Norborg, H.
Riise, T.
Myhr, K. -M.
Grytten, N.
Wergeland, S.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 712 - 712
[36] Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies
van Pesch, Vincent
Sindic, Christian J.
Fernandez, Oscar
CLINICAL NEUROLOGY AND NEUROSURGERY, 2016, 149 : 55 - 63
[37] Real-World Outcomes of DMEK: A Prospective Dutch registry study
Dunker, Suryan L.
Veldman, Manon H. J.
Winkens, Bjorn
van den Biggelaar, Frank J. H. M.
Nuijts, Rudy M. M. A.
Kruit, Pieter Jan
Dickman, Mor M.
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2021, 222 : 218 - 225
[38] Real-world study: from real-world data to real-world evidence
Wen, Yi
TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
[39] Discontinuation rates for biologic therapies in moderate-to-severe chronic plaque psoriasis in a real-world Canadian patient cohort
Gulliver, S.
Gulliver, W.
Randell, S.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 34 - 34
[40] Recurrence of disease activity after fingolimod discontinuation - observations in a real-world cohort with 433 multiple sclerosis patients.
Cerda, N.
Nagy, S.
Sinnecker, T.
Wurfel, J.
Kuhle, J.
Yaldizli, O.
Kappos, L.
Derfuss, T.
Decard, B. F.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 73 - 74

← 1 2 3 4 5 →